Vol 1, No 3 (September 27, 2012): Translational Lung Cancer Research

Establishment of a malignant pleural effusion mouse model: pathogenesis pathways

Malignant pleural effusion: further translational research is crucial

Establishment of a malignant pleural effusion mouse model with lewis lung carcinoma cell lines expressing enhanced green fluorescent protein

Role of HGF/MET axis in resistance of lung cancer to contemporary management

MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications

Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a concise review

Combined treatment with MET inhibitors and other therapies in lung cancer

First line erlotinib for NSCLC patients not selected by EGFR mutation: keep carrying the TORCH or time to let the flame die?

Turn on the TORCH before treat your patients: a lesson from a first line study in advanced NSCLC

Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study